Tian Zhang , MD, Assistant Professor of Medicine, Duke Cancer Institute, discusses strategies for the 2nd line renal cell carcinoma (RCC) patients following I-O.
Tian Zhang , MD, Assistant Professor of Medicine, Duke Cancer Institute, discusses strategies for the 2nd line renal cell carcinoma (RCC) patients following I-O.